APP and Alzheimer disease: Recently, research has shown that aucubin targets the ERK/FOS signaling pathway to inhibit the abnormal activation of microglia, thereby alleviating AD-like pathological features such as Aβ plaque deposition, neuronal damage, and inflammation due to astrocyte hyperactivation in the brains of APP/PS1 mice [122].